Actively Recruiting
A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration
Led by Kriya Therapeutics, Inc. · Updated on 2026-04-30
62
Participants Needed
3
Research Sites
133 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary to age-related macular degeneration (AMD).
CONDITIONS
Official Title
A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 55 and 80 years at consent
- Body mass index (BMI) between 19 and 34 kg/m2
- Agree to use reliable contraception for at least 12 months after treatment
- Female participants must not be pregnant or breastfeeding
- Geographic atrophy lesion meets criteria by central imaging assessment at screening
- Clear ocular media, good pupil dilation, and fixation sufficient for quality imaging
- Study eye visual acuity of 55 letters or worse (20/80 or worse) for Part 1a; 24 letters or better (about 20/320) for Part 1b and Part 2
- Fellow eye visual acuity of 5 letters or better (20/800 or better) for Part 1a; 24 letters or better (about 20/320) for Part 1b and Part 2, and must be equal or better than study eye
You will not qualify if you...
- Any eye disease besides geographic atrophy due to AMD, including exudative AMD or active macular neovascularization
- Active ocular disease affecting vision or active eye infection or uncontrolled inflammation within 3 months
- History of vitrectomy, retinal detachment, corneal transplant, or uveitis in study eye
- Any condition preventing quality eye imaging
- Medical, cognitive, or psychiatric conditions that could interfere with study assessments or increase risk
- Hospitalization within 1 year before screening that affects study participation or risk
- Clinically significant abnormal screening tests or lab results
- Contraindication to steroid treatment or increased risk of complications
- Active or recent (past 5 years) cancer except certain skin or treated localized cancers
- Eye surgery within 3 months before screening
- History of laser therapy in macula
- Intravitreal steroid treatment within 6 months before screening
- COVID-19 vaccine within 90 days before screening or planned within 6 months after treatment
- Use of systemic immunomodulatory drugs or corticosteroids in last 60 days (topical steroids allowed)
- Participation in another interventional GA clinical trial within past 12 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Kriya Clinical Study Site
Ottawa, Ontario, Canada
Actively Recruiting
2
Kriya Clinical Study Site
Tel Aviv, Israel
Actively Recruiting
3
Kriya Clinical Study Site
Christchurch, New Zealand
Actively Recruiting
Research Team
V
VP, Medical Affairs
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here